A Blue Cross Blue Shield study of one decade worth of claims for Saxenda and Wegovy found 58% of patients quit the ...

The demand for weight loss operations dropped sharply last year as the number of people opting for anti-obesity drugs such as Wegovy and Saxenda more than doubled, a study published Friday found.

Saxenda was approved by the FDA for weight loss in 2014, while Wegovy was approved in 2021. The study did not include Eli ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

The FDA has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a ...

In Singapore, GLP-1s such as Wegovy and Saxenda have been approved for weight-loss treatment. Patients can obtain them only ...

Medications such as semaglutide (branded as Ozempic and Wegovy) and tirzepatide (branded as Mounjaro ... marketed in the U.S.

But after years of development by scientists, doctors and ordinary people in clinical studies, six FDA-approved treatments, ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...